Have you been diagnosed with cancer and screened for changes in a gene called FGFR2 and/or FGFR3?

Based on a genetic test ordered by your doctor, your cancer cells may have shown that you have 1 or more of the gene changes that this drug targets. Not all doctors know about this investigational targeted therapy, so it is worth having a discussion with them before deciding what to do. The study drug (KIN-3248) is available only in this study.

No, not until additional checks to your recent medical tests and medical history are done to make sure that you can safely join this study. Every study has detailed requirements for enrollment. These are called the eligibility criteria.

You can check if you are potentially eligible for this study by completing a set of screening questions. You can find these on this web page by clicking the “Get Started” button.

Any costs related to the study visits may be covered by the study sponsor, Kinnate Biopharma, including travel costs. For more information about travel support and participation, please email [email protected].

The study sponsor, Kinnate Biopharma, provides travel support for the participant and a caregiver to the clinical study site.

More information about this and other studies can be found by searching the ClinicalTrials.gov website. You can search for this study by using this number: NCT05242822. For additional information, you can also email [email protected].

When new drugs are being studied as possible treatments for patients with a disease, they are tested in stages or “phases.” If a drug is successful during Phase 1, it moves to Phase 2. Phase 1 studies are usually conducted with a small number of participants. Researchers may conduct a Phase 1 study to learn more about how a drug (or drug combination) behaves in the body, to find a safe dose, or to test a new formulation of a drug (such as a pill versus an injection). In Phase 1 cancer studies, researchers will also start to look at how well a drug fights cancer.

A clinical study helps determine the safety and efficacy (how well a study drug works) of new treatments or vaccines. A research plan or protocol is created that outlines how study participants may receive treatments, which can include investigational medications, devices, or procedures. The study may compare a new medical approach to a standard treatment option that is already available, to a placebo with no active investigational medication, or to no intervention at all. If you decided to participate, the study staff will provide you with more information.

Study participants have the right to drop out at any time for any reason or no reason at all. The doctor or sponsor also has the right to withdraw a study participant from the study at any time for safety issues or if the participant no longer meets the study requirements.

The study staff will collect your personal information. This may include, but is not limited to, this information:

• Your name, address, telephone number, and health insurance number, where applicable
• Your age and sex
• Your ethnic and racial background
• Your lifestyle information
• Your health and medical history
• Genetic data resulting from testing your biological samples

All personal information collected for this study will be securely stored in the study medical records at the clinical study site. Sponsor staff, review boards, ethics committees (that approve and monitor studies), and others who have a need to know, such as our data hosting provider and government regulators, may check study records. Regulatory agencies, such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and others, review and approve new medicines. These agencies will be granted direct access to your information. This is so they can verify study procedures and/or data. If you share your personal data with a clinical study site, these data will be used by Citeline Connect to contact you about clinical studies and related information.